RenalGuard is designed to reduce the toxic effects of contrast media on the kidneys, which may lead to a reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients. RenalGuard Therapy is based on existing published literature, including the PRINCE study, which supports the theory that creating and maintaining a high urine output through the kidneys allows the body to eliminate contrast, reducing its toxic effects rapidly.